Case Report
Korean J Hematol 2005; 40(3):
Published online September 30, 2005
https://doi.org/10.5045/kjh.2005.40.3.188
© The Korean Society of Hematology
탈리도마이드 사용으로 혈청 M 단백은 감소하였으나 골수외 병변의 악화를 보인 다발골수종 1예
유영진, 김현수, 박영정, 엄흥식, 최상봉, 이반석, 김성록, 한태희
인제대학교 의과대학 상계백병원, 내과, 진단검사의학과
A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma
Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
Keywords Thalidomide, Multiple myeloma, Extramedullary plasmacytoma
PDF
Standard view
Export citation
Share Article
Case Report
Korean J Hematol 2005; 40(3): 188-191
Published online September 30, 2005 https://doi.org/10.5045/kjh.2005.40.3.188
Copyright © The Korean Society of Hematology.
탈리도마이드 사용으로 혈청 M 단백은 감소하였으나 골수외 병변의 악화를 보인 다발골수종 1예
유영진, 김현수, 박영정, 엄흥식, 최상봉, 이반석, 김성록, 한태희
인제대학교 의과대학 상계백병원, 내과, 진단검사의학과
A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma
Young Jin Yuh, Hyun Su Kim, Young Jung Park, Heung Sik Um, Sang Bong Choi, Ban Suck Lee, Sung Rok Kim, Tae Hee Han
Departments of, Internal Medicine and, Laboratory Medicine, Sanggyepaik Hospital, Inje University College of Medicine, Seoul, Korea
Abstract
Thalidomide is an anti-angiogenic agent widely used in patients with multiple myeloma. The response to therapy is commonly monitored using serum and/or urine M protein, as these are known to reflect the tumor burden. Although extramedullary plasmacytomas are tissues with high neovascularization, it has been suggested in some reports that the response to thalidomide in these patients may be inferior, despite changes in the serum M protein level. Herein, we report the case of a patient who newly developed hepatosplenic extramedullary plasmacytoma, despite reduction in the serum M protein level following thalidomide treatment.
Keywords: Thalidomide, Multiple myeloma, Extramedullary plasmacytoma
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
A Case of Extramedullary Plasmacytomas of Posterior Mediastinum, and Gingiva associated with Fulminant Hepatic Failure, which Developed in the Course of Multiple Myeloma
Dong Uk Kim, Kung Shic Chung, Jong Yun Cheong, Jae Cheol Choi, Jong Han Kim, Ho Jin Shin, Joo Seo Chung, Eun Yup Lee, Goon Jae Cho
Korean J Hematol 2003; 38(3): 213-216 -
Do Yeun Kim, Seock Ah Im, Chu Myong Seong, Soon Nam Lee, Soo Mee Bang, Jae Hoon Lee, Sung Soo Yoon, Byoung Kook Kim, Seon Yang Park, Myung Ju Ahn
Korean J Hematol 2002; 37(4): 259-264 -
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Res 2023; 58(4): 166-172
